Allergan has announced a new partnership with TARGET PharmaSolutions focusing on a nonalcoholic steatohepatitis (NASH) study.
TARGET-NASH is a five-year longitudinal observational study looking at patients with NASH, also known as nonalcoholic fatty liver disease. The trial has been launched in advance of related drug approvals to improve understanding of the impact of NASH and future treatment options.
“Allergan is allying with TARGET PharmaSolutions to study new approaches to treating nonalcoholic steatohepatitis.“
Involving academia, industry partners, regulatory agencies and the NASH community, the TARGET-NASH study enrolled its first patient in August 2016 and plans to involve 15,000 adults and children over its five-year duration.
The study design is disease-focused, rather than drug-specific, allowing for continuous acquisition of natural history and outcomes data as new therapies enter the market and clinical treatment paradigms evolve.
David Nicholson, chief research and development officer at Allergan, said: "This unique collaboration will help to further our collective understanding of the disease, effective modes of treatment and outcomes across the spectrum of patient groups."
This comes after the firm recently partnered with Novartis on the development of a new NASH therapy.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical